Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 34

1.

Correction: Geographic and Temporal Trends in the Molecular Epidemiology and Genetic Mechanisms of Transmitted HIV-1 Drug Resistance: An Individual-Patient- and Sequence-Level Meta-Analysis.

Rhee SY, Blanco JL, Jordan MR, Taylor J, Lemey P, Varghese V, Hamers RL, Bertagnolio S, de Wit TF, Aghokeng AF, Albert J, Avi R, Avila-Rios S, Bessong PO, Brooks JI, Boucher CA, Brumme ZL, Busch MP, Bussmann H, Chaix ML, Chin BS, D'Aquin TT, De Gascun CF, Derache A, Descamps D, Deshpande AK, Djoko CF, Eshleman SH, Fleury H, Frange P, Fujisaki S, Harrigan PR, Hattori J, Holguin A, Hunt GM, Ichimura H, Kaleebu P, Katzenstein D, Kiertiburanakul S, Kim JH, Kim SS, Li Y, Lutsar I, Morris L, Ndembi N, Kee PN, Paranjape RS, Peeters M, Poljak M, Price MA, Ragonnet-Cronin ML, Reyes-Terán G, Rolland M, Sirivichayakul S, Smith DM, Soares MA, Soriano VV, Ssemwanga D, Stanojevic M, Stefani MA, Sugiura W, Sungkanuparph S, Tanuri A, Tee KK, Truong HH, van de Vijver DA, Vidal N, Yang C, Yang R, Yebra G, Ioannidis JP, Vandamme AM, Shafer RW.

PLoS Med. 2015 Jun 1;12(6):e1001845. doi: 10.1371/journal.pmed.1001845. eCollection 2015 Jun.

2.

Geographic and temporal trends in the molecular epidemiology and genetic mechanisms of transmitted HIV-1 drug resistance: an individual-patient- and sequence-level meta-analysis.

Rhee SY, Blanco JL, Jordan MR, Taylor J, Lemey P, Varghese V, Hamers RL, Bertagnolio S, Rinke de Wit TF, Aghokeng AF, Albert J, Avi R, Avila-Rios S, Bessong PO, Brooks JI, Boucher CA, Brumme ZL, Busch MP, Bussmann H, Chaix ML, Chin BS, D'Aquin TT, De Gascun CF, Derache A, Descamps D, Deshpande AK, Djoko CF, Eshleman SH, Fleury H, Frange P, Fujisaki S, Harrigan PR, Hattori J, Holguin A, Hunt GM, Ichimura H, Kaleebu P, Katzenstein D, Kiertiburanakul S, Kim JH, Kim SS, Li Y, Lutsar I, Morris L, Ndembi N, Ng KP, Paranjape RS, Peeters M, Poljak M, Price MA, Ragonnet-Cronin ML, Reyes-Terán G, Rolland M, Sirivichayakul S, Smith DM, Soares MA, Soriano VV, Ssemwanga D, Stanojevic M, Stefani MA, Sugiura W, Sungkanuparph S, Tanuri A, Tee KK, Truong HH, van de Vijver DA, Vidal N, Yang C, Yang R, Yebra G, Ioannidis JP, Vandamme AM, Shafer RW.

PLoS Med. 2015 Apr 7;12(4):e1001810. doi: 10.1371/journal.pmed.1001810. eCollection 2015 Apr.

3.

Challenges of antiretroviral treatment monitoring in rural and remote-access regions in Africa.

Taieb F, Aghokeng AF, Eymard-Duvernay S, Chia JE, Einterz E, Mpoudi-Ngole E, Peeters M, Molina JM, Delaporte E.

AIDS Res Hum Retroviruses. 2014 Jul;30(7):623-5. doi: 10.1089/AID.2014.0035. Epub 2014 Apr 14. No abstract available.

PMID:
24645979
4.

Field evaluation of dried blood spots for routine HIV-1 viral load and drug resistance monitoring in patients receiving antiretroviral therapy in Africa and Asia.

Monleau M, Aghokeng AF, Eymard-Duvernay S, Dagnra A, Kania D, Ngo-Giang-Huong N, Touré-Kane C, Truong LX, Chaix ML, Delaporte E, Ayouba A, Peeters M; ANRS 12235 Study Group.

J Clin Microbiol. 2014 Feb;52(2):578-86. doi: 10.1128/JCM.02860-13. Epub 2013 Dec 11.

5.

Extraordinary heterogeneity of virological outcomes in patients receiving highly antiretroviral therapy and monitored with the World Health Organization public health approach in sub-saharan Africa and southeast Asia.

Aghokeng AF, Monleau M, Eymard-Duvernay S, Dagnra A, Kania D, Ngo-Giang-Huong N, Toni TD, Touré-Kane C, Truong LX, Delaporte E, Chaix ML, Peeters M, Ayouba A; ANRS 12186 Study Group.

Clin Infect Dis. 2014 Jan;58(1):99-109. doi: 10.1093/cid/cit627. Epub 2013 Sep 27.

6.

Population-based monitoring of emerging HIV-1 drug resistance on antiretroviral therapy and associated factors in a sentinel site in Cameroon: low levels of resistance but poor programmatic performance.

Billong SC, Fokam J, Aghokeng AF, Milenge P, Kembou E, Abessouguie I, Meva'a-Onglene FB, Bissek AC, Colizzi V, Mpoudi EN, Elat JB, Shiro KS.

PLoS One. 2013 Aug 26;8(8):e72680. doi: 10.1371/journal.pone.0072680. eCollection 2013.

7.

Prediction of HIV drug resistance based on virologic, immunologic, clinical, and/or adherence criteria in the Stratall ANRS 12110/ESTHER trial in Cameroon.

Boullé C, Kouanfack C, Laborde-Balen G, Aghokeng AF, Boyer S, Carrieri MP, Kazé S, Mben JM, Dontsop M, Spire B, Peeters M, Mpoudi-Ngolé E, Delaporte E, Laurent C; Stratall ANRS 12110/ESTHER Study Group.

Clin Infect Dis. 2013 Aug;57(4):604-7. doi: 10.1093/cid/cit323. Epub 2013 May 10.

8.

Susceptibility to transmitting HIV in patients initiating antiretroviral therapy in rural district hospitals in Cameroon (Stratall ANRS 12110/ESTHER Trial).

Ndziessi G, Cohen J, Kouanfack C, Marcellin F, Carrieri MP, Laborde-Balen G, Protopopescu C, Aghokeng AF, Moatti JP, Spire B, Delaporte E, Laurent C, Boyer S; Stratall ANRS 12110/ESTHER Study Group.

PLoS One. 2013 Apr 30;8(4):e62611. doi: 10.1371/journal.pone.0062611. Print 2013. Erratum in: PLoS One. 2013;8(7). doi:10.1371/annotation/8963fb4d-336a-4607-8fd9-c3404414ff9c. Carierri, Maria Patrizia [corrected to Carrieri, Maria Patrizia].

9.

Monitoring of HIV viral load, CD4 cell count, and clinical assessment versus clinical monitoring alone for antiretroviral therapy in low-resource settings (Stratall ANRS 12110/ESTHER): a cost-effectiveness analysis.

Boyer S, March L, Kouanfack C, Laborde-Balen G, Marino P, Aghokeng AF, Mpoudi-Ngole E, Koulla-Shiro S, Delaporte E, Carrieri MP, Spire B, Laurent C, Moatti JP; Stratall ANRS 12110/ESTHER Study Group.

Lancet Infect Dis. 2013 Jul;13(7):577-86. doi: 10.1016/S1473-3099(13)70073-2. Epub 2013 Apr 18.

PMID:
23602084
10.

Declining trends in early warning indicators for HIV drug resistance in Cameroon from 2008-2010: lessons and challenges for low-resource settings.

Fokam J, Billong SC, Bissek AC, Kembou E, Milenge P, Abessouguie I, Nkwescheu AS, Tsomo Z, Aghokeng AF, Ngute GD, Ndumbe PM, Colizzi V, Elat JB.

BMC Public Health. 2013 Apr 8;13:308. doi: 10.1186/1471-2458-13-308.

11.

Virological outcome and patterns of HIV-1 drug resistance in patients with 36 months' antiretroviral therapy experience in Cameroon.

Aghokeng AF, Kouanfack C, Eymard-Duvernay S, Butel C, Edoul GE, Laurent C, Koulla-Shiro S, Delaporte E, Mpoudi-Ngole E, Peeters M.

J Int AIDS Soc. 2013 Jan 31;16:18004. doi: 10.7448/IAS.16.1.18004.

12.

Time patterns of adherence and long-term virological response to non-nucleoside reverse transcriptase inhibitor regimens in the Stratall ANRS 12110/ESTHER trial in Cameroon.

Meresse M, Carrieri MP, Laurent C, Kouanfack C, Protopopescu C, Blanche J, Cohen J, Laborde-Balen G, Aghokeng AF, Spire B, Moatti JP, Delaporte E, Boyer S; Stratall ANRS 12110/ESTHER Study Group.

Antivir Ther. 2013;18(1):29-37. doi: 10.3851/IMP2535. Epub 2013 Jan 29.

PMID:
23358393
13.

Task shifting HIV care in rural district hospitals in Cameroon: evidence of comparable antiretroviral treatment-related outcomes between nurses and physicians in the Stratall ANRS/ESTHER trial.

Boullé C, Kouanfack C, Laborde-Balen G, Carrieri MP, Dontsop M, Boyer S, Aghokeng AF, Spire B, Koulla-Shiro S, Delaporte E, Laurent C; Stratall ANRSESTHER Study Group.

J Acquir Immune Defic Syndr. 2013 Apr 15;62(5):569-76. doi: 10.1097/QAI.0b013e318285f7b6.

PMID:
23337365
14.

Successful integrase inhibitor-based highly active antiretroviral therapy for a multidrug-class-resistant HIV type 1 group O-infected patient in Cameroon.

Aghokeng AF, Kouanfack C, Peeters M, Mpoudi-Ngole E, Delaporte E.

AIDS Res Hum Retroviruses. 2013 Jan;29(1):1-3. doi: 10.1089/AID.2012.0196. Epub 2012 Sep 11. No abstract available.

PMID:
22889147
15.

Early warning indicators for HIV drug resistance in Cameroon during the year 2010.

Billong SC, Fokam J, Nkwescheu AS, Kembou E, Milenge P, Tsomo Z, Dion GN, Aghokeng AF, Mpoudi EN, Ndumbe PM, Colizzi V, Elat Nfetam JB.

PLoS One. 2012;7(5):e36777. doi: 10.1371/journal.pone.0036777. Epub 2012 May 17.

16.

Failure to detect simian immunodeficiency virus infection in a large Cameroonian cohort with high non-human primate exposure.

Djoko CF, Wolfe ND, Aghokeng AF, Lebreton M, Liegeois F, Tamoufe U, Schneider BS, Ortiz N, Mbacham WF, Carr JK, Rimoin AW, Fair JN, Pike BL, Mpoudi-Ngole E, Delaporte E, Burke DS, Peeters M.

Ecohealth. 2012 Mar;9(1):17-23. doi: 10.1007/s10393-012-0751-0. Epub 2012 Mar 7.

PMID:
22395958
17.

Lamivudine-resistant HBV infection in HIV-positive patients receiving antiretroviral therapy in a public routine clinic in Cameroon.

Kouanfack C, Aghokeng AF, Mondain AM, Bourgeois A, Kenfack A, Mpoudi-Ngolé E, Ducos J, Delaporte E, Laurent C.

Antivir Ther. 2012;17(2):321-6. doi: 10.3851/IMP1911. Epub 2011 Sep 23.

PMID:
22290198
18.

Drug resistance mutations of HIV type 1 non-B viruses to integrase inhibitors in treatment-naive patients from sub-saharan countries and discordant interpretations.

Monleau M, Aghokeng AF, Nkano BA, Chaix ML, Peeters M; AC11/AC12 ANRS Working Group.

AIDS Res Hum Retroviruses. 2012 Sep;28(9):1157-60.

PMID:
22236055
19.

Scale-up of antiretroviral treatment in sub-Saharan Africa is accompanied by increasing HIV-1 drug resistance mutations in drug-naive patients.

Aghokeng AF, Kouanfack C, Laurent C, Ebong E, Atem-Tambe A, Butel C, Montavon C, Mpoudi-Ngole E, Delaporte E, Peeters M.

AIDS. 2011 Nov 13;25(17):2183-8. doi: 10.1097/QAD.0b013e32834bbbe9.

PMID:
21860346
20.

Monitoring of HIV viral loads, CD4 cell counts, and clinical assessments versus clinical monitoring alone for antiretroviral therapy in rural district hospitals in Cameroon (Stratall ANRS 12110/ESTHER): a randomised non-inferiority trial.

Laurent C, Kouanfack C, Laborde-Balen G, Aghokeng AF, Mbougua JB, Boyer S, Carrieri MP, Mben JM, Dontsop M, Kazé S, Molinari N, Bourgeois A, Mpoudi-Ngolé E, Spire B, Koulla-Shiro S, Delaporte E; Stratall ANRS 12110/ESTHER study group.

Lancet Infect Dis. 2011 Nov;11(11):825-33. doi: 10.1016/S1473-3099(11)70168-2. Epub 2011 Aug 8.

PMID:
21831714
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Loading ...
Write to the Help Desk